The Top 5 Biosimilars Articles for the Week of May 25

Here are the top 5 biosimilars articles for the week of May 25, 2020.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilars articles for the week of May 25, 2020.

Number 5: Drug rebates have survived despite the payment reforms imposed by the Medicare Modernization Act of 2003, and now payers are taking advantage of them, too, panelists noted at the NCCN 2020 Virtual Annual Conference.

Number 4: After completing a 24-week phase 3 trial, Samsung Bioepis said its biosimilar ranibizumab, SB11, has demonstrated clinical equivalence to reference Lucentis for the treatment of neovascular age-related macular degeneration.

Number 3: Fresenius Kabi’s pegfilgrastim biosimilar candidate has demonstrated a similar safety and immunogenicity profile to the reference product, Neulasta.

Number 2: On the heels of positive clinical studies, Fresenius Kabi said the European Medicines Agency will review its product application for its pegfilgrastim biosimilar.

Number 1: Biosimilars are gaining traction in the United States, but the majority of payers are putting them on an equal footing with reference drugs when it comes to coverage decisions, according to a new study.

To read all of these articles and more, visit